Cargando…

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy

Detalles Bibliográficos
Autores principales:	Rinaldi, Francesca, Federle, Lisa, Puthenparampil, Marco, Perini, Paola, Grassivaro, Francesca, Gallo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730817/ https://www.ncbi.nlm.nih.gov/pubmed/29259997 http://dx.doi.org/10.1212/NXI.0000000000000420

Ejemplares similares

Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
por: Puthenparampil, Marco, et al.
Publicado: (2017)

Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2020)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2023)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis
por: Puthenparampil, Marco, et al.
Publicado: (2017)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis
por: Liba, Zuzana, et al.
Publicado: (2017)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive Disability
por: Riccardi, Alice, et al.
Publicado: (2019)

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab
por: Kowarik, Markus C., et al.
Publicado: (2016)

Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis
por: Hu, Hannah, et al.
Publicado: (2020)

Anti-Adenylate Kinase 5 Encephalitis With Histologic Evidence of CNS Vasculitis
por: Vicino, Alex, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis
por: Miscioscia, Alessandro, et al.
Publicado: (2022)

Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy’s disease
por: Miscioscia, Alessandro, et al.
Publicado: (2023)

CNS inflammation other than multiple sclerosis: How likely is diagnosis?
por: Street, Duncan, et al.
Publicado: (2014)

Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Anti–GABA-A Receptor Antibody-Mediated Epilepsia Partialis Continua After Treatment With Alemtuzumab: A Case Report
por: Ratuszny, Dominica, et al.
Publicado: (2023)

Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
por: Signoriello, Elisabetta, et al.
Publicado: (2023)

Degos disease mimicking primary vasculitis of the CNS
por: Gmuca, Sabrina, et al.
Publicado: (2016)

Clinical Profiles in Multiple Sclerosis: Cognitive Reserve and Motor Impairment along Disease Duration
por: Maffezzini, Sabrina, et al.
Publicado: (2023)

Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
por: Gelfand, Jeffrey M., et al.
Publicado: (2014)

Asymptomatic CNS demyelination related to TNF-α inhibitor therapy
por: Ali, Farwa, et al.
Publicado: (2016)

CNS-disseminated Angiostrongylus cantonensis mimicking atypical demyelinating disease
por: Long, Daniel, et al.
Publicado: (2019)

CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19
por: Pinto, Ashwin A., et al.
Publicado: (2020)

CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection
por: Timmons, Garrett M., et al.
Publicado: (2021)

Sexual Dysfunction in Multiple Sclerosis: The Role of Executive Function
por: Marinetto, Silvia, et al.
Publicado: (2023)

BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset
por: Puthenparampil, M., et al.
Publicado: (2017)

Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study
por: Riccardi, Alice, et al.
Publicado: (2021)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Leptomeningeal inflammation in rheumatoid arthritis
por: Lattanzi, Simona, et al.
Publicado: (2014)

The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome
por: Graham, Edith, et al.
Publicado: (2020)

Unilateral Relapsing Primary CNS Vasculitis: Description of 3 Cases From a Single-Institutional Cohort of 216 Cases
por: Salvarani, Carlo, et al.
Publicado: (2023)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities
por: Margoni, Monica, et al.
Publicado: (2021)

Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis
por: Pengo, Marta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9m424ptqvl0mkrqpnape8heiur